Cytokinetics Inc. (CYTK) Tops Q1 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
Tweet
Share
E-mailGet Alerts CYTK Hot Sheet
Price: $62.33 -0.84%
Revenue Growth %: +2,004.1%
Financial Fact:
License revenues from related parties: 53.03M
Today's EPS Names:
UTMD, GCBC, ORPB, More
Revenue Growth %: +2,004.1%
Financial Fact:
License revenues from related parties: 53.03M
Today's EPS Names:
UTMD, GCBC, ORPB, More
Join SI Premium – FREE
Cytokinetics Inc. (NASDAQ: CYTK) reported Q1 EPS of ($0.18), $0.01 better than the analyst estimate of ($0.19).
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Cytokinetics to Announce Third Quarter Results on November 4, 2026
- Utah Medical Products (UTMD) Tops Q3 EPS by 87c
- Primis Financial (FRST) Misses Q3 EPS by 7c
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
